Broadening the MIND: Tafasitamab and Lenalidomide versus Synthetic Controls

Hua Jay J. Cherng; Jason R. Westin

doi:10.1158/1078-0432.CCR-22-1626

Broadening the MIND: Tafasitamab and Lenalidomide versus Synthetic Controls

Hua Jay J. Cherng, Jason R. Westin

Lymphoma-Myeloma

Research output: Contribution to journal › Article › peer-review

Abstract

Tafasitamab and lenalidomide were approved for second-line treatment of diffuse large B-cell lymphoma (DLBCL) based on a single-arm phase II study. This combination was superior to routine immunochemotherapy regimens when comparing matched observational cohorts. “Synthetic” control groups may support use of novel DLBCL therapies in the absence of randomized studies.

Original language	English (US)
Pages (from-to)	3908-3910
Number of pages	3
Journal	Clinical Cancer Research
Volume	28
Issue number	18
DOIs	https://doi.org/10.1158/1078-0432.CCR-22-1626
State	Published - Sep 15 2022

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1158/1078-0432.CCR-22-1626

Cite this

@article{d03849bc247d4d60b9b301e69696747c,

title = "Broadening the MIND: Tafasitamab and Lenalidomide versus Synthetic Controls",

abstract = "Tafasitamab and lenalidomide were approved for second-line treatment of diffuse large B-cell lymphoma (DLBCL) based on a single-arm phase II study. This combination was superior to routine immunochemotherapy regimens when comparing matched observational cohorts. “Synthetic” control groups may support use of novel DLBCL therapies in the absence of randomized studies.",

author = "Cherng, {Hua Jay J.} and Westin, {Jason R.}",

note = "Publisher Copyright: {\'O}2022 American Association for Cancer Research.",

year = "2022",

month = sep,

day = "15",

doi = "10.1158/1078-0432.CCR-22-1626",

language = "English (US)",

volume = "28",

pages = "3908--3910",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "18",

}

TY - JOUR

T1 - Broadening the MIND

T2 - Tafasitamab and Lenalidomide versus Synthetic Controls

AU - Cherng, Hua Jay J.

AU - Westin, Jason R.

N1 - Publisher Copyright: Ó2022 American Association for Cancer Research.

PY - 2022/9/15

Y1 - 2022/9/15

N2 - Tafasitamab and lenalidomide were approved for second-line treatment of diffuse large B-cell lymphoma (DLBCL) based on a single-arm phase II study. This combination was superior to routine immunochemotherapy regimens when comparing matched observational cohorts. “Synthetic” control groups may support use of novel DLBCL therapies in the absence of randomized studies.

AB - Tafasitamab and lenalidomide were approved for second-line treatment of diffuse large B-cell lymphoma (DLBCL) based on a single-arm phase II study. This combination was superior to routine immunochemotherapy regimens when comparing matched observational cohorts. “Synthetic” control groups may support use of novel DLBCL therapies in the absence of randomized studies.

UR - http://www.scopus.com/inward/record.url?scp=85138446614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85138446614&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-22-1626

DO - 10.1158/1078-0432.CCR-22-1626

M3 - Article

C2 - 35861632

AN - SCOPUS:85138446614

SN - 1078-0432

VL - 28

SP - 3908

EP - 3910

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 18

ER -

Broadening the MIND: Tafasitamab and Lenalidomide versus Synthetic Controls

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this